Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of esketamine for treatment-resistant depression
31 October 2018 - Document open to public comment until 20 November 2018
The ICER has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of esketamine (Janssen), which is currently undergoing FDA review for treatment-resistant depression with an approval decision expected in May 2019.
ICER’s report on esketamine will be the subject of a May 2019 meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees.
